

Gibson Dunn Advised Velaris Therapeutics on Sale to Alaunos Therapeutics and Concurrent Private Placement

Firm News | October 13, 2026

Gibson Dunn advised Velaris Therapeutics, a privately held biotechnology company advancing a pipeline of potentially transformative therapies for pulmonary arterial hypertension and related cardiopulmonary diseases, on its sale to Alaunos Therapeutics and on a concurrent private placement expected to fund the combined company's operations into 2029.

The firm's corporate team included partners Ryan Murr, Branden Berns, and Melanie Neary and of counsel Evan Shepherd.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Melanie E. Neary](#)

[Evan Shepherd](#)

Related Capabilities

[Life Sciences](#)